Unlike in the rest of the country, where intestinal ultrasound rarely is used in the clinic, in New York City, gastroenterologists at Mount Sinai Hospital have made IUS findings the “the fifth vital sign” for inflammatory bowel disease patient care, particularly to monitor disease. Now, new research from the institution and other centers is showing that the tool can identify patients with endoscopic recurrence and possibly predict disease outcomes and treatment response.
Trending
- Pfizer’s $10B monthly GLP-1 bet generates competitive weight loss in phase 2b (Fierce Biotech)
- ‘AI-native’ outpatient surgery startup Oath Surgical inks Nvidia partnership (Fierce Biotech)
- NVIDIA, Oath Surgical, ASCs and the Future of Physical AI in Healthcare (LSI | LinkedIn)
- UMass Successfully Performs Its First Full-Thickness Resection Device Procedure (UMass Chan Medical School)
- 5 gastroenterology physician moves in 1 month (Becker’s GI & Endoscopy)
- Artificial Intelligence on Trial: Who’s Liable When Clinical Algorithms Go Wrong? (Medscape)
- Building the Future Gastroenterologist: Why Nutrition and Lifestyle Medicine Must Be Core Competencies (ACG Case Reports Journal)
- Spray Cryotherapy Esophageal Consortium Consensus Recommendations for Liquid Nitrogen Spray Cryotherapy in Barrett’s Esophagus and Esophageal Cancer Using a Modified Delphi Process (The American Journal of Gastroenterology)
